Showing results (51-60 of 113) with videos related to

Sort By:
Pageof 12
Haematologica|February 22, 2008
High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myelomaJean El-Cheikh, Mauricette Michallet, Arnon Nagler, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 30, 2010
The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallengeFranck E Nicolini, Jean-Claude Chomel, Lydia Roy, et al.
Blood|December 21, 2011
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survivalAshley Hamilton, G Vignir Helgason, Mirle Schemionek, et al.
Hemasphere|April 21, 2021
Performances of Targeted RNA Sequencing for the Analysis of Fusion Transcripts, Gene Mutation, and Expression in Hematological MalignanciesSandrine Hayette, Béatrice Grange, Maxime Vallee, et al.
Leukemia|January 11, 2020
Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of B-cell acute lymphoblastic leukemiaDivij Verma, Costanza Zanetti, Parimala Sonika Godavarthy, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 22, 2013
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinibJorge E Cortes, Franck E Nicolini, Meir Wetzler, et al.
Nature Communications|August 3, 2021
Malignant cerebral infarction after ChAdOx1 nCov-19 vaccination: a catastrophic variant of vaccine-induced immune thrombotic thrombocytopeniaM De Michele, M Iacobucci, A Chistolini, et al.
Blood|May 13, 2011
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNetSimona Soverini, Andreas Hochhaus, Franck E Nicolini, et al.
Annals of Hematology|February 25, 2012
Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donorMauricette Michallet, Mohamad Sobh, Noel Milpied, et al.
Leukemia Research|July 8, 2010
Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily aloneFranck E Nicolini, Sandrine Hayette, Laurence Legros, et al.
Pageof 12